Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
These participants when compared with those with SARC-F values lower than 4, showed significantly higher age (72.7 ± 10.5 vs 68.02 ± 9.31 year), higher CCI (5.48 ± 2.06 vs 3.79 ± 1.29), higher FRAX derived 10-year probability of hip fractures (18.96 ± 14.3 vs 12.97 ± 13.2%) and lower handgrip strength score (19.09 ± 6.37 vs 24.77 ± 6.4 kg).Baseline clinical characteristics of participantsParticipants (n = 130)Main clinical characteristicsAge (year)70.2 ± 9.4BMI (kg/m2)24.7 ± 5SARC-F score3.4 ± 2.4Calf circumference (cm)31.9 ± 2.9Handgrip strength (kg)22.7 ± 6.7Charlson comorbidity index4.4 ± 1.710-year probability of major fractures (%)29.3 ± 13.210-year probability of hip fractures (%)14.6 ± 12.9Dmab treatment duration (months)43.2 ± 24Laboratory data25(OH)D (ng/mL)42.6 ± 16.1Serum creatinine (mg/dL)0.82 ± 0.24Serum calcium (mg/dL)9.32 ± 0.23Serum phosphorus (mg/dL)3.16 ± 0.21Alkaline phosphatase (U/L)71.2 ± 43.1CTX (ug/L)0.32 ± 0.28DXA measurementsL1-L4 BMD (g/cm2)0.75 ± 0.1Femoral neck BMD (g/cm2)0.59 ± 0.1L1-L4 T-score (SD)−2.6 ± 1.1Femoral neck T-score (SD)−2.3 ± 0.7Data are expressed as mean ± SDBMD bone mineral density, 25(OH)D 25-hydroxyvitamin D, CTX C-terminal collagen type 1 telopeptide
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were patients who had been prescribed Dmab for the secondary prevention of fragility fractures, in accordance with the national drug reimbursement legislation in Italy ().
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab
Study design awaiting verification · Aging Clinical and Experimental Research · 2025
Original publication title
Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The aim of this study was to analyze the association between muscle mass and strength with the response to denosumab in osteoporosis.
Source: AimAbstract: What methods does the paper describe?
Postmenopausal women at high fracture risk receiving denosumab (60 mg subcutaneously administered every 6 months) were considered. The likelihood of sarcopenia was estimated by administering the SARC-F questionnaire, muscle mass and performance were assessed by measuring calf circumference (CC) and hand grip strength, respectively. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry.
Source: MethodsAbstract: Results
130 women (age 70.2 ± 9.4 years) were recruited. Baseline BMD T-score values were − 2.6 ± 1.1 SD and − 2.3 ± 0.7 SD at lumbar spine and femoral neck, respectively; while CC and grip strength were 31.9 ± 2.9 cm and 22.7 ± 6.7 kg, respectively. The SARC-F score was associated with the 10-year probability of major osteoporotic fracture (r = 0.21, p < 0.05). The CC was positively associated with the T-score values of both lumbar spine (r = 0.262, p = 0.034) and femoral neck (r = 0.359, p = 0.004).
Denosumab administration (treatment duration 43 months), lead to BMD improvement by + 9.6% at the lumbar spine and + 7.3% at the femoral neck (pall < 0.05). After adjustment for comorbidities, fracture risk and treatment duration, the CC (β = 1.76, SE = 0.82, p = 0.03) and the baseline femoral BMD (β = − 94.19, SE = 26.09, p = 0.0009) were independently associated with femoral BMD gain over time.
Source: ResultsAbstract: Conclusion
In postmenopausal osteoporotic women, the CC was positively and independently associated with denosumab treatment response.
Source: ConclusionAuthors’ abstract
Background
Aging is associated with deterioration of muscle and bone health, resulting in increased fragility fracture risk. It is not known whether muscle mass and strength could impact the osteoporosis pharmacological response.
Aim
The aim of this study was to analyze the association between muscle mass and strength with the response to denosumab in osteoporosis.
Methods
Postmenopausal women at high fracture risk receiving denosumab (60 mg subcutaneously administered every 6 months) were considered. The likelihood of sarcopenia was estimated by administering the SARC-F questionnaire, muscle mass and performance were assessed by measuring calf circumference (CC) and hand grip strength, respectively. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry.
Results
130 women (age 70.2 ± 9.4 years) were recruited. Baseline BMD T-score values were − 2.6 ± 1.1 SD and − 2.3 ± 0.7 SD at lumbar spine and femoral neck, respectively; while CC and grip strength were 31.9 ± 2.9 cm and 22.7 ± 6.7 kg, respectively. The SARC-F score was associated with the 10-year probability of major osteoporotic fracture (r = 0.21, p < 0.05). The CC was positively associated with the T-score values of both lumbar spine (r = 0.262, p = 0.034) and femoral neck (r = 0.359, p = 0.004).
Denosumab administration (treatment duration 43 months), lead to BMD improvement by + 9.6% at the lumbar spine and + 7.3% at the femoral neck (pall < 0.05). After adjustment for comorbidities, fracture risk and treatment duration, the CC (β = 1.76, SE = 0.82, p = 0.03) and the baseline femoral BMD (β = − 94.19, SE = 26.09, p = 0.0009) were independently associated with femoral BMD gain over time.
Conclusion
In postmenopausal osteoporotic women, the CC was positively and independently associated with denosumab treatment response.
Publication and source details
Original title: Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab
Cecilia Oliveri; Anastasia Xourafa; Nunziata Morabito; Adele Di Giovanni; Elisa Lupo; Giorgio Basile; Agostino Gaudio; Antonino Catalano
Aging Clinical and Experimental Research · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di CataniaOpen access funding provided by Università degli Studi di Catania within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:22:45.752313+00:00
DOI: 10.1007/s40520-025-02989-7 · PMC12053332